Who are metformin, glyburide and glargine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/metformin-glyburide-and-glargine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

metformin, glyburide and glargine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

metformin, glyburide and glargine (metformin, glyburide and glargine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination antidiabetic therapy (biguanide + sulfonylurea + basal insulin). Area: Diabetes.

marketed Combination antidiabetic therapy (biguanide + sulfonylurea + basal insulin) Multiple: AMP-activated protein kinase (metformin), ATP-sensitive potassium channels (glyburide), insulin receptor (glargine) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

metformin, glyburide and glargine (metformin, glyburide and glargine) — The University of Texas Health Science Center at San Antonio. This combination therapy addresses type 2 diabetes through three complementary mechanisms: metformin reduces hepatic glucose production, glyburide stimulates pancreatic insulin secretion, and glargine provides basal insulin coverage.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
metformin, glyburide and glargine TARGET	metformin, glyburide and glargine	The University of Texas Health Science Center at San Antonio	marketed	Combination antidiabetic therapy (biguanide + sulfonylurea + basal insulin)	Multiple: AMP-activated protein kinase (metformin), ATP-sensitive potassium channels (glyburide), insulin receptor (glargine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination antidiabetic therapy (biguanide + sulfonylurea + basal insulin) class)

The University of Texas Health Science Center at San Antonio · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). metformin, glyburide and glargine — Competitive Intelligence Brief. https://druglandscape.com/ci/metformin-glyburide-and-glargine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab